In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

F-star Biotechnology Limited

http://www.f-star.com

Latest From F-star Biotechnology Limited

Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas

Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.

Deals Business Strategies

Tech Transfer Roundup: Tonix Inks Trio Of COVID-19-Focused Deals

New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.

Deals Coronavirus COVID-19

UK Biotechs Seek Government Help As Economic ‘Heart Attack’ Threatens Sector

Huge economic shock to sector could be quickly alleviated by early payment of R&D Tax Credits, says BIA.

United Kingdom BioPharmaceutical

Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech

Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • F-star Alpha Ltd.
    • F-star GmbH
    • F-star Therapeutics
UsernamePublicRestriction

Register